# Toby Sykes

> Toby Sykes is a Series C investor at Intermediate Capital Group backing Medical and Health Care. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Intermediate Capital Group](https://shizune.co/investors/profile/intermediate-capital-group)
- Total investments: 2
- Last investment: Sep 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/toby-sykes/1/26a/50b

Toby Sykes is a Series C investor at Intermediate Capital Group focused on Medical and Health Care. Toby Sykes is the Managing Director, Life Sciences at Intermediate Capital Group. Attended University of Oxford.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 100% |
| Health Care | 2 | 100% |
| Biotechnology | 2 | 100% |
| Pharmaceutical | 2 | 100% |
| Genetics | 1 | 50% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 50% |
| Series H | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 1 | 50% |
| United Kingdom | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| F2G | F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $100M | Series H | Sep 12, 2024 |  |
| Amolyt Pharma | Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. | $138.6M | Series C | Jan 06, 2023 |  |

2 of 2 investments shown.

## Co-investors
- [Sectoral Asset Management](https://shizune.co/investors/profile/sectoral-asset-management) — VC Fund, 2 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 2 deals together
- [AMR Action Fund](https://shizune.co/investors/profile/amr-action-fund) — VC Fund, 1 deal together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 1 deal together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 1 deal together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 1 deal together

## About Intermediate Capital Group

VC Fund · London, United Kingdom

Intermediate Capital Group - Mezzanine Finance. They structure and provide mezzanine finance, leveraged credit and minority equity, managing €12.1 billion of assets from third party investors and their balance sheet. They are one of the largest independent mezzanine providers in the world with investment portfolios in Europe, Asia Pacific andthe US. They also have one of the longest track records of any institutional investor in European senior loans and high yield bonds. Over two decades they have earned the trust of leading institutional investors, investment advisors and private equity sponsors. They enjoy genuine partnerships with management teams of the companies they invest in. Their international network of 11 offices is run by local investment professionals.​​​​

5 contacts available at Intermediate Capital Group.

| Name | Title | Profile |
| --- | --- | --- |
| Justin McDougall | Principal | https://shizune.co/investors/profile/justin-mcdougall |
| Toby Sykes | Managing Director, Life Sciences | https://shizune.co/investors/profile/toby-sykes |
| Wooseok Jun | Managing Director | https://shizune.co/investors/profile/wooseok-jun |
| Alan Jones | Senior Managing Director | https://shizune.co/investors/profile/alan-jones-902b |
| Benoit Durteste | Chief Investment Officer and Chief Executive Officer | https://shizune.co/investors/profile/benoit-durteste |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Toby Sykes invest in?

Toby Sykes invests primarily in Medical, Health Care and Biotechnology startups, most often at Series C and Series H stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Toby Sykes last invest?

The most recent investment recorded for Toby Sykes closed in Sep 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co